Ascendis Pharma A/S (ASND)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. This filer's financial year end could not be read from its revenue history, so quarters are labelled by the calendar. Amounts in EUR.

Revenue Annual

0 250M 500M 750M 2016: 4.6M 2017: 1.5M 2018: 10.6M 2019: 13.4M 2020: 7M 2021: 7.8M 2022: 51.2M 2023: 266.7M 2024: 363.6M 2025: 720.1M 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

Gross Profit Annual

0 250M 500M 750M 2019: 13.4M 2020: 7M 2021: 4.3M 2022: 39M 2023: 222.3M 2024: 319.4M 2025: 625.2M 2019 2020 2021 2022 2023 2024 2025

Operating Income Annual

-600M -400M -200M 0 200M 400M 600M 2016: -72.9M 2017: -111.5M 2018: -154.8M 2019: -226.7M 2020: -330.6M 2021: -451.8M 2022: -561.8M 2023: -455.5M 2024: -278.8M 2025: -136.3M 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

Net Income Annual

-600M -400M -200M 0 200M 400M 600M 2016: -68.5M 2017: -123.9M 2018: -130.1M 2019: -218M 2020: -419M 2021: -383.6M 2022: -583.2M 2023: -481.4M 2024: -378.1M 2025: -228M 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

Cost of Revenue Annual

0 35M 70M 105M 2019: 0 2020: 0 2021: 3.5M 2022: 12.1M 2023: 44.4M 2024: 44.3M 2025: 94.9M 2019 2020 2021 2022 2023 2024 2025

Operating Cash Flow Annual

-600M -400M -200M 0 200M 400M 600M 2016: -60.2M 2017: -95.1M 2018: -138.8M 2019: -175.9M 2020: -271.5M 2021: -417.6M 2022: -495.7M 2023: -467.4M 2024: -306.2M 2025: 53.9M 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

Free Cash Flow Annual

-600M -400M -200M 0 200M 400M 600M 2015: -44.5M 2016: -60.9M 2017: -96M 2018: -141.4M 2019: -181.1M 2020: -291.4M 2021: -441.4M 2022: -510.2M 2023: -469.8M 2015 2016 2017 2018 2019 2020 2021 2022 2023

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 25M 50M 75M 2016: 26.6M 2017: 33.6M 2018: 41.1M 2019: 46.5M 2020: 50.6M 2021: 54.8M 2022: 56.1M 2023: 56.3M 2024: 57.9M 2025: 60.6M 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-12.00 -8.00 -4.00 0.00 4.00 8.00 12.00 Q4 '22: -10.40 Q1 '23: -10.17 Q2 '23: -10.87 Q3 '23: -10.72 Q4 '23: -8.55 Q1 '24: -8.87 Q2 '24: -8.62 Q3 '24: -7.46 Q4 '24: -6.53 Q1 '25: -5.81 Q2 '25: -4.54 Q3 '25: -3.82 Q4 '25: -3.76 Q4 '22 Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.